Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leukotriene receptor antagonist for rectal aberrant crypt foci
jRCTs031180094Completed
- Sponsor
- Kanagawa Prefectural Industrial Technology Research Institute
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of montelukast in colon adenoma, colorectal cancer (CRC) and aberrant crypt foci (ACF) (2 arms), sponsored by Kanagawa Prefectural Industrial Technology Research Institute. Primary endpoint: Change in rectal aberrant crypt foci after 8 weeks. Started Dec 2017; status: completed.
02
Drugs
montelukast
03
Conditions
colon adenomacolorectal cancer (CRC)aberrant crypt foci (ACF)
Beyond the preview
Go deeper on jRCTs031180094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180094.